Aptar's Intranasal Delivery System Used in Phase II Clinical Study

Aptar's technology is being utilized in a new investigational nasal spray treatment.

Mar. 16, 2026 at 9:34pm

Aptar, a leading global provider of drug delivery systems, announced that its intranasal delivery technology is being used in a Phase II clinical study for an investigational nasal spray treatment called SPONTAN®. The study is taking place in Crystal Lake, Illinois.

Why it matters

Aptar's intranasal delivery systems are critical for the development of new pharmaceutical treatments that can be administered nasally. This partnership highlights Aptar's expertise in this area and the potential for SPONTAN® to offer a new therapeutic option.

The details

Aptar's proprietary intranasal delivery system is being utilized in the Phase II clinical trial for SPONTAN®, an investigational nasal spray treatment. The study is evaluating the safety and efficacy of the treatment, which is being developed by an unnamed pharmaceutical company.

  • The Phase II clinical study began in March 2026.

The players

Aptar

A leading global provider of drug delivery systems.

SPONTAN®

An investigational nasal spray treatment being evaluated in a Phase II clinical study.

Got photos? Submit your photos here. ›

What’s next

The results of the Phase II clinical study for SPONTAN® are expected to be announced later this year.

The takeaway

Aptar's intranasal delivery technology is playing a crucial role in the development of new pharmaceutical treatments that can be administered through the nose, highlighting the company's expertise in this field.